Xencor(XNCR) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Xencor Reports Second Quarter 2025 Financial Results PASADENA, Calif.--August 6, 2025-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2025 and provided recent business and clinical program updates. "Xencor is focused on execution of our clinical studies, evaluating four wholly owned XmAb® drug candidates in cancer a ...